Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Organon & Co. (NYSE:OGN) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 22 that OGN announced the completion of a global licensing agreement with Sebela Pharmaceuticals, securing exclusive rights to MIUDELLA, a hormone-free copper intrauterine device. Approved by the U.S. FDA in February 2025, MIUDELLA represents the first hormone-free copper IUD launched in the U.S. in more than four decades. The device is designed to prevent pregnancy for up to three years and offers 99% effectiveness. MIUDELLA incorporates SLIMSERT technology, featuring a flexible frame and preloaded insertion system with a 3.7mm tapered tube. The product is expected to become commercially available in late 2026.

ldutko/Shutterstock.com

Separately, on June 18, Organon & Co. (NYSE:OGN) and Samsung Bioepis announced an expansion of their development and commercialization partnership, with Organon gaining exclusive commercialization rights in Canada for Pyzchiva, a biosimilar referencing Stelara (ustekinumab). The therapy is intended for multiple inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Under the agreement, Samsung Bioepis will continue managing development, manufacturing, and regulatory responsibilities, while Organon will lead commercial activities in Canada. The expansion increases their Canadian biosimilar collaboration portfolio from five to six products, with Pyzchiva expected to launch in 2026.

Organon & Co. (NYSE:OGN) is a global healthcare company focused on women’s health, biosimilars, and established medicines, offering a portfolio of over 70 products across more than 140 markets.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.